Medical Science News

RSS

Systems biologists integrate new genetic framework to help predict adverse drug reactions

In a major step toward predicting adverse drug reactions, systems biologists at Mount Sinai School of Medicine in New York City have integrated genetic, cellular and clinical information to find out why certain medicines can trigger fatal heart arrhythmias.

21 Apr 2010

miRNAs may generate new insights on cancer and possible future treatments

Scientists are methodically unlocking the biological processes that lead to cancer, and recent discoveries with microRNAs (miRNAs) are revolutionizing their understanding and leading to clinical trials of potentially effective treatments.

21 Apr 2010

Silence Therapeutics, AstraZeneca announce one-year extension of ongoing siRNA delivery collaboration

Silence Therapeutics plc announces that the Company and AstraZeneca have agreed to a one-year extension of their ongoing small interfering RNA (siRNA) delivery collaboration. Under this collaboration, which was originally entered into in March 2008, the companies are leveraging a number of Silence's proprietary lipid delivery and targeting technologies to develop new and enhanced delivery approaches for RNA interference (RNAi) therapeutics.

21 Apr 2010

Ghent University signs agreement to use Roche's LightCycler 1536 Instrument for cancer research

Roche and Ghent University (Belgium) have signed an agreement for the use of Roche's LightCycler® 1536 Instrument in various cancer research projects in Ghent. Studies include multigene expression signature profiling on cancer research samples and, digital PCR for sensitive detection of mutant cancer cells in a background of normal cells.

21 Apr 2010

Duke University Medical Center, LabCorp form joint venture to commercialize new biomarkers

Duke University Medical Center and Laboratory Corporation of America Holdings announced today the formation of a joint venture to commercialize new biomarkers. The new entity is designed to speed the translation of newly discovered biomarkers into widely available clinical tools that can measure individual therapeutic responses, predict disease progression, and evaluate any number of biologic or disease-causing processes.

21 Apr 2010

CINJ researches identify new drug candidates that inhibits prostate cancer growth

Trying to break down a barrier that prevents effective treatment of prostate cancer, researchers from The Cancer Institute of New Jersey (CINJ) have identified candidate drugs that block a key protein responsible for tumor growth.

21 Apr 2010

ABRAXANE-bevacizumab combination therapy may exhibit potential in treatment of triple-negative breast cancers

Abraxis BioScience, Inc., a fully integrated biotechnology company, announced study results today that demonstrate a regimen of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) given in combination with bevacizumab (Avastin®) may have potential in the treatment of triple-negative breast cancers.

21 Apr 2010

Genetic dermatology tests merge with DermaGenoma

Pioneering genetic tests in key areas of dermatology today merged into one molecular dermatology research and development innovator called DermaGenoma, Inc.

21 Apr 2010

Defects in carbon nanotubes stimulate body's natural immune response: Study

Yale University engineers have found that the defects in carbon nanotubes cause T cell antigens to cluster in the blood and stimulate the body's natural immune response.

21 Apr 2010

ZenBio awarded Phase I SBIR grant to establish novel human cell-based models of NAFLD

ZenBio, Inc. announced that it has been awarded a Phase I SBIR grant to establish novel human cell-based models of non-alcoholic fatty liver disease (NAFLD) that will be useful for basic research and as a potential drug development platform. The project stems from recent efforts at ZenBio, Inc. to develop methods for differentiating adipose tissue derived progenitor cells into hepatocyte-like cells.

21 Apr 2010

Stemedica receives FDA IND approval for ischemic stroke clinical trial using allogeneic stem cells

Stemedica Cell Technologies, Inc., a world leader in stem cell research and manufacturing, announced that the U.S. Food and Drug Administration (FDA) approved an Investigational New Drug (IND) for a clinical trial for ischemic stroke using Stemedica's high potency proprietary allogeneic stem cells (adult human).

21 Apr 2010

NEDD9 protein plays significant role in development of HER2-driven breast cancer: Researchers

Researchers at Fox Chase Cancer Center have identified a potentially significant molecular player in the development of aggressive breast cancer. The team's findings show that a protein called NEDD9 is critical in the formation of breast tumors induced by high levels of the cell-surface receptor HER2/neu in mice.

21 Apr 2010

Semafore Pharmaceuticals' SF1126 PI3K-mTOR inhibitor demonstrates broad anti-tumor activity in lymphoma

Semafore Pharmaceuticals today announced the presentation of data demonstrating that SF1126, a novel small molecule inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), has broad preclinical anti-tumor activity in multiple myeloma and lymphoma. Data were presented in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C.

21 Apr 2010

New web-based service for analyzing, visualizing and managing DNA sequencing data

DNAnexus, Inc. today announced the commercial launch of its web-based service for analyzing, visualizing, and managing next-generation DNA sequencing data. Andreas Sundquist, Ph.D., co-founder and CEO, will introduce the solution publicly for the first time today at the annual Bio-IT World Conference and Expo in Boston, Massachusetts.

20 Apr 2010

Platelet rich plasma helps speed healing and bone formation following tooth removal

The use of platelet rich plasma (PRP) following tooth removal appears to speed healing and bone formation, according to an article in the Journal of Oral Implantology.

20 Apr 2010

MUC1 expression indicates progression of pediatric inflammatory bowel disease

Millions of people are afflicted with inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, and 30 percent of new cases occur in childhood. Mucin 1, an epithelial mucin that has been shown to elicit both an immune response and to have altered glycosylation in disease, may be a noninvasive indicator of the progression of these illnesses.

20 Apr 2010

Affymetrix introduces new service for obtaining allele-specific copy number data from FFPE samples

Affymetrix, Inc. today announced the launch of the Affymetrix® MIP Copy Number Service, designed for cancer researchers using challenging FFPE samples. With the MIP Copy Number Service, scientists can now obtain high-quality allele-specific copy number data from FFPE samples. The service is available for research use only exclusively through the Affymetrix® Research Services Laboratory (ARSL).

20 Apr 2010

Genetic defect in protein glycogenin can lead to cardiac arrest

Researchers have discovered a new disorder linked to heart problems that stems from a genetic defect in the protein glycogenin. In a worst case scenario, disruption of this protein's function can lead to cardiac arrest, which is exactly what happened to the young man whose case triggered the investigation at Sahlgrenska University Hospital at the University of Gothenburg, Sweden, that led to a brand new diagnosis.

20 Apr 2010

NextBio announces new Sequence-Centric module for mining high throughput array and sequencing data

NextBio today announced the latest evolution of its innovative life science research platform, adding new capabilities for the integration and mining of high-throughput array and next-generation sequencing data. The new NextBio Sequence-Centric module enables researchers to effectively explore and utilize massive amounts of public and internally generated sequencing data, while allowing organizations to create corporate-wide genomic data platforms to serve the needs of their global research teams.

20 Apr 2010

Striking down breast cancer related gene patent may not impact industry, says New York attorney

The recent decision in a Federal District Court in New York to strike down a patent for the breast cancer related BRCA-1 gene may not have the broad impact on the technology industry it had originally been feared to, says a New York attorney.

20 Apr 2010

Medical Science News

Systems biologists integrate new genetic framework to help predict adverse drug reactions

miRNAs may generate new insights on cancer and possible future treatments

Silence Therapeutics, AstraZeneca announce one-year extension of ongoing siRNA delivery collaboration

Ghent University signs agreement to use Roche's LightCycler 1536 Instrument for cancer research

Duke University Medical Center, LabCorp form joint venture to commercialize new biomarkers

CINJ researches identify new drug candidates that inhibits prostate cancer growth

ABRAXANE-bevacizumab combination therapy may exhibit potential in treatment of triple-negative breast cancers

Genetic dermatology tests merge with DermaGenoma

Defects in carbon nanotubes stimulate body's natural immune response: Study

ZenBio awarded Phase I SBIR grant to establish novel human cell-based models of NAFLD

Stemedica receives FDA IND approval for ischemic stroke clinical trial using allogeneic stem cells

NEDD9 protein plays significant role in development of HER2-driven breast cancer: Researchers

Semafore Pharmaceuticals' SF1126 PI3K-mTOR inhibitor demonstrates broad anti-tumor activity in lymphoma

New web-based service for analyzing, visualizing and managing DNA sequencing data

Platelet rich plasma helps speed healing and bone formation following tooth removal

MUC1 expression indicates progression of pediatric inflammatory bowel disease

Affymetrix introduces new service for obtaining allele-specific copy number data from FFPE samples

Genetic defect in protein glycogenin can lead to cardiac arrest

NextBio announces new Sequence-Centric module for mining high throughput array and sequencing data

Striking down breast cancer related gene patent may not impact industry, says New York attorney

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Latest News